CF PharmTech, Inc. disclosed that on 20 May 2026 it repurchased 32,000 H shares on the Hong Kong Stock Exchange, representing 0.0106 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.

The shares were bought back at prices ranging from HKD 20.00 to HKD 20.52, translating to a volume-weighted average of HKD 20.2153 and an aggregate consideration of HKD 0.65 million. All repurchased shares are being held as treasury shares.

Following the transaction, outstanding shares (excluding treasury shares) declined to 301.37 million, while the treasury-share balance increased to 851,500. Total issued shares, including treasury stock, remained unchanged at 302.22 million.

The repurchases form part of the mandate approved on 16 December 2025, which authorises the company to buy back up to 30.22 million shares. To date, 851,500 shares—or 0.28 % of the authorised limit—have been repurchased under this mandate. In accordance with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or selling treasury shares until 19 June 2026.